Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEODE II: Viekira Pak + Low-Dose Ribavirin in GT1a HCV
NCT02609659Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of Viekira Pak in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Oct 2015; status: completed.
02
Drugs
Viekira Pak
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02609659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02609659.